NervGen Pharma Corp
9UA
Company Profile
Business description
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
Contact
112-970 Burrard Street
Unit 1290
VancouverBCV6Z 2R4
CANT: +1 778 731-1711
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
12
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,203.90 | 28.80 | 0.35% |
| CAC 40 | 7,573.76 | 37.50 | 0.50% |
| DAX 40 | 22,271.67 | 29.22 | 0.13% |
| Dow JONES (US) | 40,083.34 | 30.16 | -0.08% |
| FTSE 100 | 8,417.34 | 2.09 | 0.02% |
| HKSE | 21,971.96 | 8.78 | -0.04% |
| NASDAQ | 17,264.66 | 118.28 | -0.68% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,098.89 | 81.05 | 0.67% |
| S&P 500 | 5,503.44 | 21.77 | -0.39% |
| S&P/ASX 200 | 7,997.10 | 28.90 | 0.36% |
| SSE Composite Index | 3,288.41 | 6.65 | -0.20% |